Literature DB >> 6696726

Mapping of the properdin-binding site in the third component of complement.

J D Lambris, J Alsenz, T F Schulz, M P Dierich.   

Abstract

The properdin-binding site in the human third complement component (C3) was mapped by using isolated C3b, C3c, alpha- and beta-chains of C3 and C3 polypeptide fragments and an enzyme-linked-immunosorbent-assay procedure. The C3 chains and the polypeptide fragments were purified to homogeneity by preparative sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. The alpha-chain polypeptides included a 68 kDa and a 43 kDa polypeptide, which were generated by cleavage of C3b with factors I and H, and a 40 kDa, 33 kDa (C3d) and 27 kDa polypeptide, which were generated by cleavage of C3b with porcine elastase. It was shown that properdin binds to C3b, C3c, alpha-chain, and to the 43 kDa (factor-I + H-derived), as well as to 40 kDa (elastase-derived) alpha-chain fragment, but not to the beta-chain 68 kDa, 33 kDa (C3d) and 27 kDa alpha-chain fragments. Thus the binding site for properdin resides on the 40-43 kDa C-terminal alpha-chain fragment of C3.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696726      PMCID: PMC1153213          DOI: 10.1042/bj2170323

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  12 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

Review 2.  Complement ligand-receptor interactions that mediate biological responses.

Authors:  D T Fearon; W W Wong
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

3.  Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range.

Authors:  S Udenfriend; S Stein; P Böhlen; W Dairman; W Leimgruber; M Weigele
Journal:  Science       Date:  1972-11-24       Impact factor: 47.728

4.  Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.

Authors:  O Götze; R G Medicus; H J Müller-Eberhard
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

5.  Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.

Authors:  G D Ross; J D Lambris; J A Cain; S L Newman
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  Assay of membrane complement receptors (CR1 and CR2) with C3b- and C3d-coated fluorescent microspheres.

Authors:  J D Lambris; G D Ross
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

Review 7.  The proteolytic activation systems of complement.

Authors:  K B Reid; R R Porter
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

8.  Preparation of human factor D of the alternative pathway of complement.

Authors:  K B Reid; D M Johnson; J Gagnon; R Phohaska
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

9.  Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.

Authors:  J Chapitis; I H Lepow
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

10.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  11 in total

1.  Regulation of C5 convertase activity by properdin, factors B and H.

Authors:  J M Weiler
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Antigenic relationship between the alpha-chain of C3, a leucocyte-surface antigen involved in the activation of phagocytic cells, and a 50,000 MW B-cell antigen.

Authors:  T F Schulz; H Scharfenberger; J D Lambris; P Rieber; G Riethmüller; M P Dierich
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

3.  Functional and structural insight into properdin control of complement alternative pathway amplification.

Authors:  Dennis V Pedersen; Lubka Roumenina; Rasmus K Jensen; Trine Af Gadeberg; Chiara Marinozzi; Capucine Picard; Tania Rybkine; Steffen Thiel; Uffe Bs Sørensen; Cordula Stover; Veronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  EMBO J       Date:  2017-03-06       Impact factor: 11.598

4.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

5.  Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-08-01       Impact factor: 3.857

Review 6.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression.

Authors:  B Nilsson; D Grossberger; K Nilsson Ekdahl; P Riegert; D J Becherer; U R Nilsson; J D Lambris
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

8.  Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H.

Authors:  J Alsenz; J D Lambris; T F Schulz; M P Dierich
Journal:  Biochem J       Date:  1984-12-01       Impact factor: 3.857

9.  Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.

Authors:  M T Aguado; J D Lambris; G C Tsokos; R Burger; D Bitter-Suermann; J D Tamerius; F J Dixon; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 10.  Properdin: approaching four decades of research.

Authors:  K K Maves; J M Weiler
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.